Concepedia

Author

Auli Ropo

Santen (Finland)

Also Known As

A ROPO, A Ropo, A. Ropo, AULI ROPO, Auli Ropo

52

Publications

1.6K

Citations

25

H-Index

27

Concepts

All Affiliations

Santen (Finland)Tampere University HospitalKuopio University HospitalHelsinki University Hospital
AR

About

Auli Ropo is an author at Santen (Finland) specializing in medicine, ophthalmology, and glaucoma.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

374

2

Anesthesia

3

3

105

3

Health Sciences

1

1

46

4

Social Sciences

1

1

34

5

Biomedical Engineering

1

1

25

Auli Ropo

×

34

Publications

1.4K

Citations

24

H-Index

YearCitations

Switching from a preserved to a preservative‐free prostaglandin preparation in topical glaucoma medication

Hannu Uusitalo, Enping Chen, Norbert Pfeiffer,

Acta Ophthalmologica

2010

165

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open‐angle glaucoma and ocular hypertension: 24‐month results of a randomized, double‐masked phase III study

Hannu Uusitalo, Lutz E. Pillunat, Auli Ropo

Acta Ophthalmologica

2010

113

Efficacy and safety levels of preserved and preservative‐free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis

Thomas Hamacher, Juhani Airaksinen, Ville Saarela,

Acta Ophthalmologica

2008

82

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials

Hannu Uusitalo, Kai Kaarniranta, Yuri S. Astakhov,

Clinical ophthalmology

2016

65

Pharmacokinetics, efficacy and safety profiles of preserved and preservative‐free tafluprost in healthy volunteers

Hannu Uusitalo, Kai Kaarniranta, Auli Ropo

Acta Ophthalmologica

2008

56

Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study

Makoto Aihara, Auli Ropo, Fenghe Lu,

Japanese Journal of Ophthalmology

2020

55

Efficacy and systemic side‐effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel

Hannu Uusitalo, Juanita Niño, Kari U. O. Tahvanainen,

Acta Ophthalmologica Scandinavica

2005

54

Efficacy, Safety, and Tolerability of Preservative-Free Fixed Combination of Tafluprost 0.0015%/Timolol 0.5% Versus Concomitant Use of the Ingredients

Gábor Holló, Anton Hommer, Alfonso Antón López,

Journal of Ocular Pharmacology and Therapeutics

2014

52

A Phase II Study on the Duration and Stability of the Intraocular Pressure-Lowering Effect and Tolerability of Tafluprost Compared With Latanoprost

Carlo Enrico Traverso, Auli Ropo, Marina Papadia,

Journal of Ocular Pharmacology and Therapeutics

2010

52

Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study

Tuomo Nieminen, Hannu Uusitalo, Jukka Mäenpää,

European Journal of Clinical Pharmacology

2005

49

Page 1